After “Peculiar” Turns, Abbvie Loses Patent Claim For Humira In India
This article was originally published in PharmAsia News
Executive Summary
The Indian Patent Office has dismissed the patent claims on Humira on grounds like prior art and insufficient and ambiguous descriptions. The benefit of the patent opposition brought on by Glenmark by default goes to Zydus Cadila, which recently launched the drug.